Medical Cannabis
What is Medical Cannabis?
History, Science, and Clinical Evidence
A comprehensive clinical and pharmacological review: from the earliest documented records 5,000 years ago to medicines approved by the EMA and the FDA. Essential foundations for contemporary medical practice with cannabinoids.
Table of Contents
- Clinical definition and differentiation
- Ancient history: 5,000 years of use
- Western validation — 19th Century
- 20th-century prohibition
- Mechoulam and the isolation of THC
- The Endocannabinoid System
- Timeline of pharmacological milestones
- From the laboratory to the clinic
- Current knowledge gaps and research
- Lessons for medical practice
Clinical Definition and Differentiation of Medical Cannabis
Medical Cannabis refers to the use of preparations derived from the Cannabis sativa L. plant—or its isolated cannabinoids—for therapeutic purposes, under medical prescription, within the context of an established clinical diagnosis and with a defined therapeutic goal.
— Operational definition. Receta Cannabis Spain, 2025.This definition entails a fundamental distinction that medical professionals must internalize: Medical Cannabis is not recreational Cannabis with a medical indication. It constitutes a distinct pharmacological field with its own identified active pharmaceutical ingredients, described mechanisms of action, standardized formulations, and a specific regulatory framework in Spain under Real Decreto 903/2025.
The Cannabis sativa L. plant contains more than 500 identified chemical compounds, of which at least 144 are cannabinoids—molecules that interact with the human endocannabinoid system. The two cannabinoids with the most documented clinical relevance are Δ⁹-tetrahydrocannabinol (THC), the primary psychoactive component, and cannabidiol (CBD), which is non-psychoactive and possesses an anti-inflammatory, anticonvulsant, and anxiolytic profile.
The difference between medicinal and recreational use does not lie solely in clinical intent, but in dose standardization, controlled administration routes, clinical follow-up, and evidence-based indication. These four pillars legitimate the medical prescription of cannabinoids.
Key clinical distinction: Medical Cannabis is not equivalent to "therapeutic marijuana" in the colloquial sense. In Spain, authorized cannabinoid medicines are pharmaceutical products with defined compositions, dosages, and routes of administration, subject to the same safety and efficacy requirements as any other pharmaceutical product within the National Health System (SNS).
From a pharmacological perspective, cannabinoids act upon the Endocannabinoid System (ECS), a retrograde lipid signaling system present in virtually all human tissues. This system regulates critical homeostatic functions such as pain modulation, inflammatory response, appetite, sleep-wake cycles, memory, and mood. A comprehensive understanding of the ECS is therefore the biological foundation of all cannabinoid pharmacology.
5,000 Years of Documented Medicinal Use
Cannabis represents one of the medicinal plants with the longest documented historical continuity. Its therapeutic use is not a contemporary trend: it is a millennia-old practice spanning civilizations, continents, and radically different medical systems, consistently converging on the same clinical indications: pain, inflammation, spasms, and sleep disorders.
Cross-cultural convergence: The fact that civilizations without mutual contact—China, India, Egypt, Greece—independently recorded the exact same therapeutic indications (pain, inflammation, spasms) constitutes, from a historical epidemiological perspective, evidence of empirical efficacy with remarkable consistency.
Western Validation: Cannabis Enters Evidence-Based Medicine
The 19th century marked the transition of Cannabis from traditional folk medicine into scientific Western medicine. This transition was driven by systematic clinical methodology that, for the first time, applied rigorous standards of observation and documentation characteristic of modern medicine.
William B. O'Shaughnessy (1809–1873), an Irish physician serving with the British Army in India, conducted between 1833 and 1839 the first systematic clinical evaluation of Cannabis in patients suffering from tetanus, rabies, cholera, and rheumatism. His seminal 1839 publication, "On the Preparations of the Indian Hemp, or Gunjah", in the Transactions of the Medical and Physical Society of Bengal, is regarded as the inception of Western cannabinoid pharmacology.
His clinical findings documented:
- Significant efficacy in severe muscle spasms (tetanus, rabies)
- Potent analgesic properties in neuropathic pain
- Anticonvulsant efficacy in pediatric epilepsy
- An acceptable safety profile under controlled titration
- Absence of lethal toxicity across observed clinical cases
O'Shaughnessy's pioneering work catalyzed widespread clinical adoption across Western medicine. By the late 19th century, Cannabis had become a standard component of medical practice throughout Europe and North America, integrated into major pharmacopoeias:
| Pharmacopoeia / Institution | Period | Documented Indications |
|---|---|---|
| United States Pharmacopeia (USP) | 1850 – 1942 | Chronic pain, insomnia, dysmenorrhea, muscle spasms |
| British Pharmacopoeia | 1864 – 1932 | Migraine, neuralgia, insomnia. Prescribed by Sir John Russell Reynolds to Queen Victoria for dysmenorrhea |
| Eli Lilly & Co. | 1880s – 1930s | Industrial manufacturing of standardized Cannabis extracts and fluid tinctures |
| Parke-Davis | 1880s – 1930s | Cannabis tinctures for analgesia, anxiety relief, and sedation |
| Merck Index | 1889 | First inclusion of Cannabis as an established reference medicinal agent |
Relevant historical evidence: In 1890, Sir John Russell Reynolds, Physician-in-Ordinary to Queen Victoria, published in The Lancet that he had prescribed Cannabis for more than 30 years in the treatment of dysmenorrhea, neuralgia, and insomnia, describing its clinical utility as being "of inestimable value."
The principal technical challenge during the 19th century was potency variability between botanical preparations: without knowledge of the specific active constituents or precise analytical assaying, dosing remained unpredictable. This challenge, which resulted in sporadic cases of overmedication, served as one rationale—though far from the primary one—for its subsequent removal from pharmacopoeias. The definitive pharmacological solution arrived in 1964 with the isolation of THC.
The Anatomy of Prohibition: A Non-Scientific Setback
The removal of Cannabis from Western pharmacopoeias and its subsequent global criminalization did not stem from emerging scientific evidence indicating toxicity or clinical inefficacy. Rather, it was driven by a convergence of political, economic, and sociodemographic factors that physicians must comprehend to contextualize current gaps in medical literature.
"Marijuana is the most violent drug in the history of mankind."
— Attributed to Harry J. Anslinger, Commissioner of the US Federal Bureau of Narcotics (1930–1962), chief architect of global Cannabis prohibition.| Year | Legislation | Scientific Impact |
|---|---|---|
| 1937 | Marihuana Tax Act (USA) | Prohibitive excise taxation effectively criminalized medical prescription, despite official AMA opposition. Cannabis was officially removed from the USP in 1942. |
| 1961 | UN Single Convention on Narcotic Drugs | Global scheduling of Cannabis alongside raw opiates, dismissing 5,000 years of documented therapeutic history and extensive empirical literature. |
| 1970 | Controlled Substances Act (USA) | Schedule I classification: designated as having "no currently accepted medical use and high potential for abuse." Placed alongside heroin, creating severe regulatory barriers that halted clinical research for decades. |
Direct clinical impact on modern practice: The clinical knowledge gaps that complicate contemporary cannabinoid prescribing—such as limited phase III randomized controlled trials, lack of official dosing guidelines, and sparse safety data in vulnerable cohorts—are the direct consequence of research prohibitions imposed throughout the 20th century, rather than an inherent absence of therapeutic potential.
Raphael Mechoulam and the Isolation of Δ⁹-THC (1964)
In 1964, Dr. Raphael Mechoulam and his research group at the Hebrew University of Jerusalem accomplished the isolation, complete structural elucidation, and total chemical synthesis of Δ⁹-tetrahydrocannabinol (THC), the primary psychoactive cannabinoid. This breakthrough marked the beginning of modern cannabinoid pharmacology.
Mechoulam's discovery definitively solved the central technical problem that had hindered 19th-century therapeutics: for the first time, medical science had access to a chemically pure, analytically verifiable, and pharmaceutically titratable molecule.
The immediate and downstream implications were profound:
- Identification of the primary active compound: Established THC as the primary psychoactive agent, separating its effects from the non-intoxicating therapeutic actions mediated by other cannabinoids.
- Pharmaceutical standardization: Chemical characterization enabled precise dosing, overcoming the erratic potency of crude botanical preparations.
- Foundational scientific research: Paved the way for structure-activity relationship studies and spurred the systematic search for biological receptor targets.
Scientific legacy: Dr. Raphael Mechoulam (1930–2023) is universally recognized as the "father of cannabinoid research." Over an extraordinary career, he characterized THC and CBD, co-discovered the endocannabinoids anandamide and 2-AG, and formulated the entourage effect hypothesis. He was repeatedly nominated for the Nobel Prize in Physiology or Medicine.
The Discovery of the Endocannabinoid System
Following the isolation of THC, a fundamental biological question emerged: why does the human central nervous system possess high-affinity binding sites for a plant-derived lipid? The answer unfolded between 1988 and 1995 with the characterization of the Endocannabinoid System (ECS), an endogenous retrograde lipid-signaling network that proved to be one of the most widespread and physiologically vital regulatory systems in the human body.
| Component | Discovery | Primary Anatomical Distribution | Key Physiological Role |
|---|---|---|---|
| CB1 Receptor | Howlett (1988) · Matsuda (1990) | Predominantly CNS: cerebral cortex, hippocampus, basal ganglia, cerebellum, dorsal horn of spinal cord | Modulation of nociception, synaptic transmission, motor control, memory, appetite, affective regulation |
| CB2 Receptor | Munro (1993) | Immune cells (B/T lymphocytes, macrophages), peripheral tissues, microglia, gastrointestinal tract | Immunomodulation, regulation of inflammatory cascades, peripheral nociceptive signaling |
| Anandamide (AEA) | Mechoulam et al. (1992) | Ubiquitous — synthesized on-demand in target membranes from phospholipid precursors | Endogenous partial agonist of CB1 and CB2. Regulates central pain pathways, appetite, mood, and extinction of aversive memories |
| 2-Arachidonoylglycerol (2-AG) | Mechoulam et al. (1995) | Ubiquitous — present in brain tissue at concentrations ~170-fold higher than AEA | Full agonist at CB1 and CB2 receptors. Primary mediator of retrograde synaptic plasticity and neuroprotection |
Fundamental clinical significance: The ECS operates as a master homeostatic regulator, maintaining internal physiological equilibrium across nociceptive, immunological, metabolic, and neurological axes. The presence of this dedicated, conserved biological apparatus provides the empirical foundation validating pharmacological cannabinoid therapeutics with the same rigorous scientific justification applied to adrenergic or opioid pharmacotherapy.
Pharmacological Milestones: From 1899 to the Present
Pharmacological knowledge concerning cannabinoids evolved along a discontinuous trajectory, stalled by decades of prohibitive legislation before undergoing rapid acceleration from the late 1980s onward. This timeline provides clinicians with historical perspective regarding the foundation of available clinical evidence.
From Laboratory to Prescription: Approved Cannabinoid Medicines
Translating preclinical pharmacology into licensed prescription therapeutics has advanced steadily. The following pharmaceutical agents represent the current standard of regulated cannabinoid pharmacotherapy, accessible in Spain via specialist medical prescription.
Knowledge Gaps and Contemporary Research Frontiers
Despite significant scientific progress over recent decades, substantial knowledge gaps persist as a direct consequence of the regulatory and research barriers enforced throughout the 20th century.
Active research frontiers: Investigating the molecular basis of the entourage effect, characterizing minor phytocannabinoids (CBG, THCV, CBC), and developing peripherally restricted CB2-selective agonists devoid of psychotropic CNS effects represent high-priority translational objectives.
Historical Lessons for Contemporary Medical Practice
Scientific References
- Mechoulam R, Gaoni Y. A Total Synthesis of dl-Δ1-Tetrahydrocannabinol. J Am Chem Soc. 1965.
- Devane WA, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992.
- National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. 2017.
Specialized Medical Training
Looking to prescribe Medical Cannabis with clinical rigor and full legal certainty?
Accredited medical program aligned with Real Decreto 903/2025. 40 hours, 4 comprehensive modules, 100% online.
View Training Program →